A Wöckel1, R Wolters2, T Wiegel3, I Novopashenny2, W Janni1, R Kreienberg1, M Wischnewsky2, L Schwentner4. 1. Department of Gynecology and Obstetrics, University Ulm, Ulm. 2. Department of Mathematics and Computer Science, University Bremen, Bremen. 3. Department of Radiotherapy and Radiooncology, University Ulm, Ulm, Germany. 4. Department of Gynecology and Obstetrics, University Ulm, Ulm. Electronic address: lukas.schwentner@yahoo.de.
Abstract
BACKGROUND: Radiotherapy (RT) is proven to be an important backbone for adjuvant therapy in randomized, controlled trials, but it is unclear if these effects are provable in a daily routine cohort of breast cancer patients. This study sought to answer the following questions in a daily routine cohort of breast cancer patients: 1. Does guideline-adherent RT improve primary breast cancer patient survival? 2. Is breast-conserving surgery (BCS) followed by RT equal to a mastectomy (MA) with regard to outcome parameters? 3. Does adjuvant RT compensate for an incomplete tumor resection (R1)? PATIENTS AND METHODS: In this retrospective, multicenter cohort study, we investigated data from 8935 primary breast cancer patients recruited from 17 participating certified breast cancer centers in Germany between 1992 and 2008. Guideline adherence based on internationally validated guidelines. RESULTS: The patients who received guideline-adherent RT for primary breast cancer were associated with significantly improved survival parameters [recurrence-free survival (RFS): P < 0.001; overall survival (OS): P < 0.001] compared with patients who did not receive guideline-adherent adjuvant RT. Furthermore, the results demonstrated that there were no significant differences in RFS and OS between BCS followed by RT and MA [RFS: P = 0.293; OS: P = 0.104]. Adjuvant RT did not improve the outcome of patients receiving nonguideline-adherent incomplete tumor resection via BCS (R1); these patients showed a significantly impaired RFS [P < 0.001] and OS [P < 0.001] compared with patients who underwent guideline-adherent complete tumor resection via BCS (R0). In addition, non-guideline-adherent RT after MA (overtherapy) did not significantly influence survival [RFS: P = 0.838; OS: P = 0.613]. CONCLUSION: Our study confirms the importance of guideline-adherent adjuvant RT. It shows highly significant associations between RFS or OS and guideline adherent RT. Nevertheless, inadequate (R1-) surgical resection in a daily routine cohort of patients increases the risk of local recurrence and appears not to be compensated by the following RT.
BACKGROUND: Radiotherapy (RT) is proven to be an important backbone for adjuvant therapy in randomized, controlled trials, but it is unclear if these effects are provable in a daily routine cohort of breast cancerpatients. This study sought to answer the following questions in a daily routine cohort of breast cancerpatients: 1. Does guideline-adherent RT improve primary breast cancerpatient survival? 2. Is breast-conserving surgery (BCS) followed by RT equal to a mastectomy (MA) with regard to outcome parameters? 3. Does adjuvant RT compensate for an incomplete tumor resection (R1)? PATIENTS AND METHODS: In this retrospective, multicenter cohort study, we investigated data from 8935 primary breast cancerpatients recruited from 17 participating certified breast cancer centers in Germany between 1992 and 2008. Guideline adherence based on internationally validated guidelines. RESULTS: The patients who received guideline-adherent RT for primary breast cancer were associated with significantly improved survival parameters [recurrence-free survival (RFS): P < 0.001; overall survival (OS): P < 0.001] compared with patients who did not receive guideline-adherent adjuvant RT. Furthermore, the results demonstrated that there were no significant differences in RFS and OS between BCS followed by RT and MA [RFS: P = 0.293; OS: P = 0.104]. Adjuvant RT did not improve the outcome of patients receiving nonguideline-adherent incomplete tumor resection via BCS (R1); these patients showed a significantly impaired RFS [P < 0.001] and OS [P < 0.001] compared with patients who underwent guideline-adherent complete tumor resection via BCS (R0). In addition, non-guideline-adherent RT after MA (overtherapy) did not significantly influence survival [RFS: P = 0.838; OS: P = 0.613]. CONCLUSION: Our study confirms the importance of guideline-adherent adjuvant RT. It shows highly significant associations between RFS or OS and guideline adherent RT. Nevertheless, inadequate (R1-) surgical resection in a daily routine cohort of patients increases the risk of local recurrence and appears not to be compensated by the following RT.
Entities:
Keywords:
breast cancer; cohort; guideline adherence; radiotherapy; survival
Authors: R Wolters; A C Regierer; L Schwentner; V Geyer; K Possinger; R Kreienberg; M B Wischnewsky; A Wöckel Journal: Eur J Cancer Date: 2011-07-07 Impact factor: 9.162
Authors: Lee H Schwamm; Gregg C Fonarow; Mathew J Reeves; Wenqin Pan; Michael R Frankel; Eric E Smith; Gray Ellrodt; Christopher P Cannon; Li Liang; Eric Peterson; Kenneth A Labresh Journal: Circulation Date: 2008-12-15 Impact factor: 29.690
Authors: Richard Pötter; Michael Gnant; Werner Kwasny; Christoph Tausch; Leonore Handl-Zeller; Brigitte Pakisch; Susanne Taucher; Josef Hammer; Gero Luschin-Ebengreuth; Marianne Schmid; Felix Sedlmayer; Michael Stierer; Georg Reiner; Karin Kapp; Friedrich Hofbauer; Andrea Rottenfusser; Sabine Pöstlberger; Karin Haider; Wolfgang Draxler; Raimund Jakesz Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-23 Impact factor: 7.038
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Deirdre A Hill; Sarah Friend; Lesley Lomo; Charles Wiggins; Marc Barry; Eric Prossnitz; Melanie Royce Journal: Breast Cancer Res Treat Date: 2018-03-22 Impact factor: 4.872
Authors: Ciprian Tănăsescu; Dragos Serban; Andrei Moisin; Carmen Popa; Ramona Coca; George Iancu; Mihail Silviu Tudosie; Daniel Ovidiu Costea; Bogdan Socea; Corneliu Tudor; Gabriel Andrei Gangura; Laura Carina Tribus; Gabriel Catalin Smarandache Journal: Exp Ther Med Date: 2021-11-17 Impact factor: 2.447
Authors: Lukas Schwentner; Reyn Van Ewijk; Thorsten Kühn; Felix Flock; Riccardo Felberbaum; Maria Blettner; Rolf Kreienberg; Wolfgang Janni; Achim Wöckel; Susanne Singer Journal: Support Care Cancer Date: 2016-01-27 Impact factor: 3.603
Authors: Arvydas Laurinavicius; Andrew R Green; Aida Laurinaviciene; Giedre Smailyte; Valerijus Ostapenko; Raimundas Meskauskas; Ian O Ellis Journal: Oncotarget Date: 2015-12-01
Authors: Nora H Trabulsi; Alaa A Shabkah; Reem Ujaimi; Omar Iskanderani; Mai S Kadi; Nuran Aljabri; Liane Sharbatly; Manal N AlOtaibi; Ali H Farsi; Mohammed O Nassif; Abdulaziz M Saleem; Nouf Y Akeel; Nadim H Malibary; Ali A Samkari Journal: Cureus Date: 2021-06-08
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872
Authors: Ignacio Ricci-Cabello; Adrián Vásquez-Mejía; Carlos Canelo-Aybar; Ena Niño de Guzman; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Ivan Solà; Yang Song; Luciana Neamtiu; Elena Parmelli; Zuleika Saz-Parkinson; Pablo Alonso-Coello Journal: BMC Health Serv Res Date: 2020-10-07 Impact factor: 2.655